查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1403494

2030 年肺动脉高血压市场预测：按产品、类型、给药途径、最终用户和地区进行的全球分析

Pulmonary Arterial Hypertension Market Forecasts to 2030 - Global Analysis By Type, Product, Route of Administration, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，2023 年全球肺动脉高血压市场规模为 54 亿美元，预计预测期内复合年增长率为 7.4%，到 2030 年将达到 89 亿美元。

肺动脉高血压是一种罕见且危险的疾病，其特征是向肺部供血的动脉血压升高。呼吸困难和心臟衰竭是肺动脉压力升高引起的一些併发症。市面上有多种治疗方法旨在控制和缓解 PAH 症状，最终目标是改善患者的整体健康状况和前景。

根据《美国管理医疗杂誌》报道，PAH 是一种罕见疾病，在美国和欧洲每百万人中有 15 至 50 人受到影响。 52.6% 的 PAH 病例是特发性、遗传性和厌食症所致。 PAH 通常发生在 30 岁至 60 岁之间的女性。

危险因子增加

PAH 通常与结缔组织疾病、先天性心臟疾病和肝病等潜在疾病有关。随着这些危险因子的发生率在全球范围内增加，PAH 的盛行率也在增加。此外，久坐的生活方式和接触环境毒素等生活方式因素也会导致多环芳烃患者的增加。人口高龄化进一步增加了风险，因为 PAH 更常见于老年人。这些风险因素的负担日益加重，导致受 PAH 影响的人数迅速增加，推动了对创新治疗方法、药物介入和医学进步的需求。

与治疗选择相关的高成本

现有治疗方案的高成本是肺动脉高血压市场的主要障碍。 PAH 治疗（包括磷酸二酯酶 5 抑制剂、内皮素受体拮抗和细胞週期蛋白类似物）的费用对于患者和医疗保健系统来说都是高昂的。 PAH 的诊断和治疗很复杂，需要专门的医疗基础设施和知识。这些经济和实际限制使得提供有效的多环芳烃治疗变得困难，并突出需要更容易获得和价格合理的治疗选择。

开发创新治疗方法

肺动脉高血压市场提供了许多机会，包括开发新型治疗策略和针对性药物。技术和科学的发展使得找到针对 PAH 根本原因的新的、更有效的治疗方法成为可能。改善早期诊断和提高意识将使我们能够收治更多患者。

治疗选择有限

肺动脉高血压市场因治疗选择匮乏和难以创造有效的治疗方法而受到严重威胁。由于 PAH 是一种严重的疾病，由于疾病复杂的病理以及对新作用机制的需求，新治疗药物的开发具有挑战性。然而，缺乏多样化和有针对性的治疗方法可能会限制患者的选择并阻碍整个 PAH 市场的扩张。

COVID-19 的影响：

COVID-19 的疫情对市场产生了重大影响。封锁期间，肺动脉高压患者难以获得医疗照护和治疗。由于医疗保健系统的中断，PAH 患者的诊断和治疗开始出现延误。此外，新型多环芳烃治疗方法的研究和开发受到阻碍，影响了潜在治疗方法的研发。医疗资源的重新配置和经济的不确定性进一步加剧了PAH市场的压力。疫情对市场动态和多环芳烃管理的长期影响仍然令人担忧，解决这些问题需要继续努力。

磷酸二酯酶 5 (PDE-5) 抑制剂预计在预测期内将成为最大的细分市场

磷酸二酯酶-5 (PDE-5) 抑制剂部分在预测期内占据最大份额。他达拉非和Sildenafil等磷酸二酯酶 5 (PDE-5) 抑制剂对于肺动脉高血压市场至关重要。这些药物透过抑制 5 型磷酸二酯酶发挥作用，从而扩张肺动脉并改善血流。这些抑制剂透过特异性靶向 PDE-5 酶来放鬆肺血管平滑肌细胞并降低肺动脉压力。 PDE-5抑制剂广泛用于PAH的治疗，且常采用联合治疗以增强疗效。

预计学名药在预测期内的复合年增长率最高。

随着时间的推移，学名药行业显示出盈利增长，因为它涉及品牌 PAH 治疗的非专利药替代品。学名药为患者提供了更实惠的选择，因为它们是生物等效的替代品。该部分将使 PAH 治疗更容易获得，并允许更多患者购买和服用处方药物。这些因素正在推动该领域的成长。

占比最高的地区

北美肺动脉高血压（PAH）市场预计将占据最大份额。由于治疗方法的进步、诊断方法的增强和认识的提高，PAH 诊断的频率正在增加。此外，北美广泛的医疗保健系统和高昂的医疗费用提供了最先进的治疗方法和药物。此外，北美多环芳烃研究、开发和普及的关键因素是製药公司、研究机构和医疗保健提供者之间的合作。

复合年增长率最高的地区：

欧洲肺动脉高血压市场在一段时间内持续成长。患者和医疗保健专业人员的治疗方法改进和诊断意识的提高正在推动该地区的市场成长。欧洲也拥有完善的医疗保健基础设施，有助于获得这些先进的治疗方法。此外，该地区製药公司、研究机构和医疗机构之间的合作正在推动新药和治疗方法的推出，进一步推动该地区的成长。

免费客製化服务：

订阅此报告的客户可以存取以下免费自订选项之一：

  • 公司简介
    • 其他市场公司的综合分析（最多 3 家公司）
    • 主要企业SWOT分析（最多3家企业）
  • 区域分割
    • 根据客户兴趣对主要国家的市场估计、预测和复合年增长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第二章 前言

  • 概述
  • 相关利益者
  • 调查范围
  • 调查方法
    • 资料探勘
    • 资料分析
    • 资料检验
    • 研究途径
  • 调查来源
    • 主要调查来源
    • 二次调查来源
    • 先决条件

第三章市场趋势分析

  • 促进因素
  • 抑制因素
  • 机会
  • 威胁
  • 产品分析
  • 最终用户分析
  • 新兴市场
  • 新型冠状病毒感染疾病（COVID-19）的影响

第4章波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争公司之间的敌对关係

第五章全球肺动脉高血压市场：依产品

  • 内皮素受体拮抗
  • 可溶性鸟苷酸环化酶 (sGC) 刺激剂
  • 磷酸二酯酶 5 (PDE-5) 抑制剂
  • 细胞週期蛋白类似物
  • 其他产品

第六章全球肺动脉高血压市场：依类型

  • 创新的
  • 非专利的
  • 品牌
  • 其他类型

第七章全球肺动脉高血压市场：依给药途径

  • 口服
  • 静脉
  • 其他给药途径

第八章全球肺动脉高血压市场：依最终用户分类

  • 医院
  • 零售药房
  • 网路药房
  • 其他最终用户

第九章全球肺动脉高血压市场：按地区

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 欧洲其他地区
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东/非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东/非洲

第10章 主要进展

  • 合约、伙伴关係、协作和合资企业
  • 收购和合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第十一章 公司简介

  • Actelion Pharmaceuticals ltd.
  • Bayer
  • Eli lilly and company
  • Gilead Sciences, Inc.
  • Gsk Plc
  • Hubei Gedian Humanwell Pharmaceutical Co., Ltd
  • Johnson & Johnson
  • Lupin
  • Pfizer Inc
  • Sun Pharmaceutical Industries Ltd.
  • Taizhou Tianrui Chemical Co., Ltd
  • Teva Pharmaceutical Industries Ltd.
  • United Therapeutics Corporation
  • Viatris Inc
Product Code: SMRC24719

According to Stratistics MRC, the Global Pulmonary Arterial Hypertension Market is accounted for $5.4 billion in 2023 and is expected to reach $8.9 billion by 2030 growing at a CAGR of 7.4% during the forecast period. High blood pressure in the arteries supplying blood to the lungs is a defining feature of pulmonary arterial hypertension, a rare and dangerous condition. Breathing difficulties and heart failure are some of the complications that can result from this elevated pressure in the pulmonary arteries. This market includes a variety of treatments intended to control and alleviate PAH symptoms, with the ultimate goal of enhancing patients' general health and outlook.

According to The American Journal of Managed Care, PAH is a rare disorder found in 15 to 50 persons per million within the United States and Europe. Idiopathic, heritable, and anorexigen-induced PAH make up 52.6% of all PAH cases. Usually, PAH affects women aged between 30 and 60 years.

Market Dynamics:

Driver:

Increasing prevalence of risk factors

PAH is often associated with underlying conditions such as connective tissue diseases, congenital heart defects, and liver disease, among others. As the incidence of these risk factors rises globally, so does the prevalence of PAH. Additionally, lifestyle factors such as sedentary behavior and exposure to environmental toxins contribute to the escalation of PAH cases. The aging population further amplifies the risk, as PAH is more commonly diagnosed in older individuals. This growing burden of risk factors has led to an upsurge in the number of people affected by PAH, driving the demand for innovative treatments, pharmaceutical interventions, and medical advancements.

Restraint:

High costs associated with treatment options

The high cost of available treatment options is a major barrier to the pulmonary arterial hypertension market. The cost of PAH drugs, which include phosphodiesterase-5 inhibitors, endothelin receptor antagonists, and prostacyclin analogs, can be prohibitive for patients and healthcare systems alike. Optimizing disease management is made more difficult by the complex nature of PAH diagnosis and treatment, which calls for specialized healthcare infrastructure and knowledge. These financial and practical limitations make it difficult to provide effective PAH care and emphasize the need for more readily available and reasonably priced therapeutic options.

Opportunity:

Development of innovative therapeutic approaches

The market for pulmonary arterial hypertension offers a number of opportunities, including the creation of novel treatment strategies and focused medications. Technological and scientific developments have made it possible to find new treatment approaches that are more effective in addressing the underlying causes of PAH. A larger patient pool may result from improved early diagnosis and raised awareness.

Threat:

Limited treatment options

The market for pulmonary arterial hypertension is seriously threatened by the scarcity of treatment options and the difficulty of creating efficient treatments. Because PAH is an uncommon and serious illness, developing new medications is difficult due to the disease's complex pathophysiology and the requirement for novel mechanisms of action. However, the lack of varied and focused treatment options could restrict patient options and impede the PAH market's overall expansion.

COVID-19 Impact:

The COVID-19 pandemic has influentially impacted the market. During lockdowns, patients with PAH had difficulty getting access to medical care and treatments. Patients with PAH experienced delays in diagnosis and treatment initiation due to disruptions in the healthcare system. Additionally, the pipeline of possible medications was impacted by hampered research and development efforts for novel PAH therapies. The PAH market was further strained by reallocations of healthcare resources and economic uncertainties. The pandemic's long-term effects on market dynamics and PAH management are still a worry, and solving these issues will take continued work.

The Phosphodiesterase-5 (PDE-5) Inhibitors segment is expected to be the largest during the forecast period

Phosphodiesterase-5 (PDE-5) Inhibitors segment commanded the largest share over the projected period. Phosphodiesterase-5 (PDE-5) Inhibitors like tadalafil and sildenafil are essential to the market for pulmonary arterial hypertension. These medications function by blocking the phosphodiesterase type 5 enzyme, which causes the pulmonary arteries to dilate and improve blood flow. These inhibitors lower pulmonary arterial pressure by relaxing smooth muscle cells in the pulmonary vessels by specifically targeting the PDE-5 enzyme. PDE-5 inhibitors are frequently used in combination therapy to improve treatment efficacy because they are widely used in the management of PAHs.

The generics segment is expected to have the highest CAGR during the forecast period

The generics segment is showing profitable growth over the period of time as it deals with the accessibility of generic substitutes for name-brand PAH drugs. Generic medications offer patients more affordable options since they are bioequivalent substitutes for their name-brand counterparts. This section helps make PAH therapies more accessible, which makes it possible for a larger group of patients to afford and take their prescribed drugs. These elements are boosting segments growth.

Region with largest share:

The pulmonary arterial hypertension (PAH) market in North America is expected to hold largest share. The frequency of PAH diagnoses is on the rise, which can be attributed to advances in treatment options, enhanced diagnostic methods, and increased awareness. Furthermore, more access to cutting-edge treatments and pharmaceuticals is made possible by North America's extensive healthcare system and high healthcare spending. Moreover, a major factor in the advancement of PAH research, development, and uptake in the North American region has been the cooperative efforts of pharmaceutical companies, research institutes, and healthcare providers.

Region with highest CAGR:

The European market for pulmonary arterial hypertension has grown consistently over a period of time. Improvements in treatment options, growing awareness among patients and healthcare professionals in diagnosis have all fueled market growth in the region. Europe also boasts a well-established healthcare infrastructure, facilitating the accessibility of these advanced treatments. Additionally, the collaborative efforts between pharmaceutical companies, research institutions, and healthcare organizations in the region have resulted in the introduction of novel drugs and therapies, further propelling regional growth.

Key players in the market:

Some of the key players in Pulmonary Arterial Hypertension market include Actelion pharmaceuticals ltd., Bayer, Eli lilly and company, Gilead sciences, inc., Gsk plc , Hubei Gedian Humanwell Pharmaceutical Co., Ltd, Johnson & johnson , Lupin, Pfizer inc, Sun pharmaceutical industries ltd., Taizhou Tianrui Chemical Co., Ltd, Teva pharmaceutical industries ltd., United therapeutics corporation and Viatris inc.

Key Developments:

In December 2023, G+Flas Life Sciences and Bayer AG have signed a letter of intent (LOI) to collaborate on the development of novel Crispr genome-edited tomato varieties that are nutritionally enhanced with vitamin D3. This LOI underscores the shared interest of G+FLAS and Bayer AG in developing tomato seeds that not only meet high commercial standards but also incorporate cutting-edge genetic traits through G+Flas's Crispr genome editing technology.

In October 2023, Viatris Inc., a global healthcare company, announced it has received an offer for the divestiture of substantially all of its Over-the-Counter (OTC) business, and has entered into definitive agreements to divest its Women's Healthcare business. With this announcement the Company has delivered on its commitment to announce agreements on all planned divestitures by the end of 2023 within the Company's previously communicated range, after considering the estimated retained value.

Products Covered:

  • Endothelin Receptor Antagonists
  • Soluble Guanylate Cyclase (SGC) Stimulators
  • Phosphodiesterase-5 (PDE-5) Inhibitors
  • Prostacyclin Analogs
  • Other Products

Types Covered:

  • Innovative
  • Generics
  • Branded
  • Other Types

Route of Administrations Covered:

  • Oral
  • Intravenous/ subcutaneous
  • Other Routes of Administrations

End Users Covered:

  • Hospitals
  • Retail Pharmacies
  • Online Pharmacies
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Pulmonary Arterial Hypertension Market, By Product

  • 5.1 Introduction
  • 5.2 Endothelin Receptor Antagonists
  • 5.3 Soluble Guanylate Cyclase (sGC) Stimulators
  • 5.4 Phosphodiesterase-5 (PDE-5) Inhibitors
  • 5.5 Prostacyclin Analogs
  • 5.6 Other Products

6 Global Pulmonary Arterial Hypertension Market, By Type

  • 6.1 Introduction
  • 6.2 Innovative
  • 6.3 Generics
  • 6.4 Branded
  • 6.5 Other Types

7 Global Pulmonary Arterial Hypertension Market, By Route of Administration

  • 7.1 Introduction
  • 7.2 Oral
  • 7.3 Intravenous
  • 7.4 Other Routes of Administrations

8 Global Pulmonary Arterial Hypertension Market, By End User

  • 8.1 Introduction
  • 8.2 Hospitals
  • 8.3 Retail Pharmacies
  • 8.4 Online Pharmacies
  • 8.5 Other End Users

9 Global Pulmonary Arterial Hypertension Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.6 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 Actelion Pharmaceuticals ltd.
  • 11.2 Bayer
  • 11.3 Eli lilly and company
  • 11.4 Gilead Sciences, Inc.
  • 11.5 Gsk Plc
  • 11.6 Hubei Gedian Humanwell Pharmaceutical Co., Ltd
  • 11.6 Johnson & Johnson
  • 11.8 Lupin
  • 11.9 Pfizer Inc
  • 11.10 Sun Pharmaceutical Industries Ltd.
  • 11.11 Taizhou Tianrui Chemical Co., Ltd
  • 11.12 Teva Pharmaceutical Industries Ltd.
  • 11.13 United Therapeutics Corporation
  • 11.14 Viatris Inc

List of Tables

  • Table 1 Global Pulmonary Arterial Hypertension Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Pulmonary Arterial Hypertension Market Outlook, By Product (2021-2030) ($MN)
  • Table 3 Global Pulmonary Arterial Hypertension Market Outlook, By Endothelin Receptor Antagonists (2021-2030) ($MN)
  • Table 4 Global Pulmonary Arterial Hypertension Market Outlook, By Soluble Guanylate Cyclase (sGC) Stimulators (2021-2030) ($MN)
  • Table 5 Global Pulmonary Arterial Hypertension Market Outlook, By Phosphodiesterase-5 (PDE-5) Inhibitors (2021-2030) ($MN)
  • Table 6 Global Pulmonary Arterial Hypertension Market Outlook, By Prostacyclin Analogs (2021-2030) ($MN)
  • Table 7 Global Pulmonary Arterial Hypertension Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 8 Global Pulmonary Arterial Hypertension Market Outlook, By Type (2021-2030) ($MN)
  • Table 9 Global Pulmonary Arterial Hypertension Market Outlook, By Innovative (2021-2030) ($MN)
  • Table 10 Global Pulmonary Arterial Hypertension Market Outlook, By Generics (2021-2030) ($MN)
  • Table 11 Global Pulmonary Arterial Hypertension Market Outlook, By Branded (2021-2030) ($MN)
  • Table 12 Global Pulmonary Arterial Hypertension Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 13 Global Pulmonary Arterial Hypertension Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 14 Global Pulmonary Arterial Hypertension Market Outlook, By Oral (2021-2030) ($MN)
  • Table 15 Global Pulmonary Arterial Hypertension Market Outlook, By Intravenous (2021-2030) ($MN)
  • Table 16 Global Pulmonary Arterial Hypertension Market Outlook, By Other Routes of Administrations (2021-2030) ($MN)
  • Table 17 Global Pulmonary Arterial Hypertension Market Outlook, By End User (2021-2030) ($MN)
  • Table 18 Global Pulmonary Arterial Hypertension Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 19 Global Pulmonary Arterial Hypertension Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
  • Table 20 Global Pulmonary Arterial Hypertension Market Outlook, By Online Pharmacies (2021-2030) ($MN)
  • Table 21 Global Pulmonary Arterial Hypertension Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 22 North America Pulmonary Arterial Hypertension Market Outlook, By Country (2021-2030) ($MN)
  • Table 23 North America Pulmonary Arterial Hypertension Market Outlook, By Product (2021-2030) ($MN)
  • Table 24 North America Pulmonary Arterial Hypertension Market Outlook, By Endothelin Receptor Antagonists (2021-2030) ($MN)
  • Table 25 North America Pulmonary Arterial Hypertension Market Outlook, By Soluble Guanylate Cyclase (sGC) Stimulators (2021-2030) ($MN)
  • Table 26 North America Pulmonary Arterial Hypertension Market Outlook, By Phosphodiesterase-5 (PDE-5) Inhibitors (2021-2030) ($MN)
  • Table 27 North America Pulmonary Arterial Hypertension Market Outlook, By Prostacyclin Analogs (2021-2030) ($MN)
  • Table 28 North America Pulmonary Arterial Hypertension Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 29 North America Pulmonary Arterial Hypertension Market Outlook, By Type (2021-2030) ($MN)
  • Table 30 North America Pulmonary Arterial Hypertension Market Outlook, By Innovative (2021-2030) ($MN)
  • Table 31 North America Pulmonary Arterial Hypertension Market Outlook, By Generics (2021-2030) ($MN)
  • Table 32 North America Pulmonary Arterial Hypertension Market Outlook, By Branded (2021-2030) ($MN)
  • Table 33 North America Pulmonary Arterial Hypertension Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 34 North America Pulmonary Arterial Hypertension Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 35 North America Pulmonary Arterial Hypertension Market Outlook, By Oral (2021-2030) ($MN)
  • Table 36 North America Pulmonary Arterial Hypertension Market Outlook, By Intravenous (2021-2030) ($MN)
  • Table 37 North America Pulmonary Arterial Hypertension Market Outlook, By Other Routes of Administrations (2021-2030) ($MN)
  • Table 38 North America Pulmonary Arterial Hypertension Market Outlook, By End User (2021-2030) ($MN)
  • Table 39 North America Pulmonary Arterial Hypertension Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 40 North America Pulmonary Arterial Hypertension Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
  • Table 41 North America Pulmonary Arterial Hypertension Market Outlook, By Online Pharmacies (2021-2030) ($MN)
  • Table 42 North America Pulmonary Arterial Hypertension Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 43 Europe Pulmonary Arterial Hypertension Market Outlook, By Country (2021-2030) ($MN)
  • Table 44 Europe Pulmonary Arterial Hypertension Market Outlook, By Product (2021-2030) ($MN)
  • Table 45 Europe Pulmonary Arterial Hypertension Market Outlook, By Endothelin Receptor Antagonists (2021-2030) ($MN)
  • Table 46 Europe Pulmonary Arterial Hypertension Market Outlook, By Soluble Guanylate Cyclase (sGC) Stimulators (2021-2030) ($MN)
  • Table 46 Europe Pulmonary Arterial Hypertension Market Outlook, By Phosphodiesterase-5 (PDE-5) Inhibitors (2021-2030) ($MN)
  • Table 48 Europe Pulmonary Arterial Hypertension Market Outlook, By Prostacyclin Analogs (2021-2030) ($MN)
  • Table 49 Europe Pulmonary Arterial Hypertension Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 50 Europe Pulmonary Arterial Hypertension Market Outlook, By Type (2021-2030) ($MN)
  • Table 51 Europe Pulmonary Arterial Hypertension Market Outlook, By Innovative (2021-2030) ($MN)
  • Table 52 Europe Pulmonary Arterial Hypertension Market Outlook, By Generics (2021-2030) ($MN)
  • Table 53 Europe Pulmonary Arterial Hypertension Market Outlook, By Branded (2021-2030) ($MN)
  • Table 54 Europe Pulmonary Arterial Hypertension Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 55 Europe Pulmonary Arterial Hypertension Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 56 Europe Pulmonary Arterial Hypertension Market Outlook, By Oral (2021-2030) ($MN)
  • Table 57 Europe Pulmonary Arterial Hypertension Market Outlook, By Intravenous (2021-2030) ($MN)
  • Table 58 Europe Pulmonary Arterial Hypertension Market Outlook, By Other Routes of Administrations (2021-2030) ($MN)
  • Table 59 Europe Pulmonary Arterial Hypertension Market Outlook, By End User (2021-2030) ($MN)
  • Table 60 Europe Pulmonary Arterial Hypertension Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 61 Europe Pulmonary Arterial Hypertension Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
  • Table 62 Europe Pulmonary Arterial Hypertension Market Outlook, By Online Pharmacies (2021-2030) ($MN)
  • Table 63 Europe Pulmonary Arterial Hypertension Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 64 Asia Pacific Pulmonary Arterial Hypertension Market Outlook, By Country (2021-2030) ($MN)
  • Table 65 Asia Pacific Pulmonary Arterial Hypertension Market Outlook, By Product (2021-2030) ($MN)
  • Table 66 Asia Pacific Pulmonary Arterial Hypertension Market Outlook, By Endothelin Receptor Antagonists (2021-2030) ($MN)
  • Table 67 Asia Pacific Pulmonary Arterial Hypertension Market Outlook, By Soluble Guanylate Cyclase (sGC) Stimulators (2021-2030) ($MN)
  • Table 68 Asia Pacific Pulmonary Arterial Hypertension Market Outlook, By Phosphodiesterase-5 (PDE-5) Inhibitors (2021-2030) ($MN)
  • Table 69 Asia Pacific Pulmonary Arterial Hypertension Market Outlook, By Prostacyclin Analogs (2021-2030) ($MN)
  • Table 70 Asia Pacific Pulmonary Arterial Hypertension Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 71 Asia Pacific Pulmonary Arterial Hypertension Market Outlook, By Type (2021-2030) ($MN)
  • Table 72 Asia Pacific Pulmonary Arterial Hypertension Market Outlook, By Innovative (2021-2030) ($MN)
  • Table 73 Asia Pacific Pulmonary Arterial Hypertension Market Outlook, By Generics (2021-2030) ($MN)
  • Table 74 Asia Pacific Pulmonary Arterial Hypertension Market Outlook, By Branded (2021-2030) ($MN)
  • Table 75 Asia Pacific Pulmonary Arterial Hypertension Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 76 Asia Pacific Pulmonary Arterial Hypertension Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 77 Asia Pacific Pulmonary Arterial Hypertension Market Outlook, By Oral (2021-2030) ($MN)
  • Table 78 Asia Pacific Pulmonary Arterial Hypertension Market Outlook, By Intravenous (2021-2030) ($MN)
  • Table 79 Asia Pacific Pulmonary Arterial Hypertension Market Outlook, By Other Routes of Administrations (2021-2030) ($MN)
  • Table 80 Asia Pacific Pulmonary Arterial Hypertension Market Outlook, By End User (2021-2030) ($MN)
  • Table 81 Asia Pacific Pulmonary Arterial Hypertension Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 82 Asia Pacific Pulmonary Arterial Hypertension Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
  • Table 83 Asia Pacific Pulmonary Arterial Hypertension Market Outlook, By Online Pharmacies (2021-2030) ($MN)
  • Table 84 Asia Pacific Pulmonary Arterial Hypertension Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 85 South America Pulmonary Arterial Hypertension Market Outlook, By Country (2021-2030) ($MN)
  • Table 86 South America Pulmonary Arterial Hypertension Market Outlook, By Product (2021-2030) ($MN)
  • Table 86 South America Pulmonary Arterial Hypertension Market Outlook, By Endothelin Receptor Antagonists (2021-2030) ($MN)
  • Table 88 South America Pulmonary Arterial Hypertension Market Outlook, By Soluble Guanylate Cyclase (sGC) Stimulators (2021-2030) ($MN)
  • Table 89 South America Pulmonary Arterial Hypertension Market Outlook, By Phosphodiesterase-5 (PDE-5) Inhibitors (2021-2030) ($MN)
  • Table 90 South America Pulmonary Arterial Hypertension Market Outlook, By Prostacyclin Analogs (2021-2030) ($MN)
  • Table 91 South America Pulmonary Arterial Hypertension Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 92 South America Pulmonary Arterial Hypertension Market Outlook, By Type (2021-2030) ($MN)
  • Table 93 South America Pulmonary Arterial Hypertension Market Outlook, By Innovative (2021-2030) ($MN)
  • Table 94 South America Pulmonary Arterial Hypertension Market Outlook, By Generics (2021-2030) ($MN)
  • Table 95 South America Pulmonary Arterial Hypertension Market Outlook, By Branded (2021-2030) ($MN)
  • Table 96 South America Pulmonary Arterial Hypertension Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 97 South America Pulmonary Arterial Hypertension Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 98 South America Pulmonary Arterial Hypertension Market Outlook, By Oral (2021-2030) ($MN)
  • Table 99 South America Pulmonary Arterial Hypertension Market Outlook, By Intravenous (2021-2030) ($MN)
  • Table 100 South America Pulmonary Arterial Hypertension Market Outlook, By Other Routes of Administrations (2021-2030) ($MN)
  • Table 101 South America Pulmonary Arterial Hypertension Market Outlook, By End User (2021-2030) ($MN)
  • Table 102 South America Pulmonary Arterial Hypertension Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 103 South America Pulmonary Arterial Hypertension Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
  • Table 104 South America Pulmonary Arterial Hypertension Market Outlook, By Online Pharmacies (2021-2030) ($MN)
  • Table 105 South America Pulmonary Arterial Hypertension Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 106 Middle East & Africa Pulmonary Arterial Hypertension Market Outlook, By Country (2021-2030) ($MN)
  • Table 106 Middle East & Africa Pulmonary Arterial Hypertension Market Outlook, By Product (2021-2030) ($MN)
  • Table 108 Middle East & Africa Pulmonary Arterial Hypertension Market Outlook, By Endothelin Receptor Antagonists (2021-2030) ($MN)
  • Table 109 Middle East & Africa Pulmonary Arterial Hypertension Market Outlook, By Soluble Guanylate Cyclase (sGC) Stimulators (2021-2030) ($MN)
  • Table 110 Middle East & Africa Pulmonary Arterial Hypertension Market Outlook, By Phosphodiesterase-5 (PDE-5) Inhibitors (2021-2030) ($MN)
  • Table 111 Middle East & Africa Pulmonary Arterial Hypertension Market Outlook, By Prostacyclin Analogs (2021-2030) ($MN)
  • Table 112 Middle East & Africa Pulmonary Arterial Hypertension Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 113 Middle East & Africa Pulmonary Arterial Hypertension Market Outlook, By Type (2021-2030) ($MN)
  • Table 114 Middle East & Africa Pulmonary Arterial Hypertension Market Outlook, By Innovative (2021-2030) ($MN)
  • Table 115 Middle East & Africa Pulmonary Arterial Hypertension Market Outlook, By Generics (2021-2030) ($MN)
  • Table 116 Middle East & Africa Pulmonary Arterial Hypertension Market Outlook, By Branded (2021-2030) ($MN)
  • Table 117 Middle East & Africa Pulmonary Arterial Hypertension Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 118 Middle East & Africa Pulmonary Arterial Hypertension Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 119 Middle East & Africa Pulmonary Arterial Hypertension Market Outlook, By Oral (2021-2030) ($MN)
  • Table 120 Middle East & Africa Pulmonary Arterial Hypertension Market Outlook, By Intravenous (2021-2030) ($MN)
  • Table 121 Middle East & Africa Pulmonary Arterial Hypertension Market Outlook, By Other Routes of Administrations (2021-2030) ($MN)
  • Table 122 Middle East & Africa Pulmonary Arterial Hypertension Market Outlook, By End User (2021-2030) ($MN)
  • Table 123 Middle East & Africa Pulmonary Arterial Hypertension Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 124 Middle East & Africa Pulmonary Arterial Hypertension Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
  • Table 125 Middle East & Africa Pulmonary Arterial Hypertension Market Outlook, By Online Pharmacies (2021-2030) ($MN)
  • Table 126 Middle East & Africa Pulmonary Arterial Hypertension Market Outlook, By Other End Users (2021-2030) ($MN)